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ABSTRACT
The approval of one of the first anti-vascular
endothelial growth factor (VEGF) agents for the
treatment of neovascular age-related macular
degeneration one decade ago marked the
beginning of a new era in the management of
several sight-threatening retinal diseases. Since
then, emerging evidence has demonstrated the
utility of these therapies for the treatment of
other ocular conditions characterized by
elevated VEGF levels. In this article we review
current perspectives on the use of anti-VEGF
drugs as adjuvant therapy in the management
of neovascular glaucoma (NVG). The use of
anti-VEGFs for modifying wound healing in
glaucoma filtration surgery (GFS) is also
reviewed. Selected studies investigating the use
of anti-VEGF agents or antimetabolites in GFS
or the management of NVG have demonstrated
that these agents can improve surgical
outcomes. However, anti-VEGF agents have
yet to demonstrate specific advantages over
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the more established agents commonly used
today. Further studies are needed to evaluate
the duration of action, dosing intervals, and
toxicity profile of these treatments.
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INTRODUCTION
Glaucoma comprises a group of disorders
characterized by a distinctive optic neuropathy
that leads to progressive asymptomatic visual
field loss. It is thought that loss of vision in
glaucoma is associated with damage to the optic
nerve and retina that results in irreversible
retinal ganglion cell damage. Glaucoma is
currently the leading cause of irreversible
blindness worldwide. It has been estimated
that the total number of patients with
glaucoma will be close to 80 million by 2020 [1].
Because glaucomatous neuropathy is usually
associated with elevation of intraocular pressure
(IOP), the main objective of all available
treatment options comprises a meaningful IOP
reduction to a predetermined level, which is
commensurate with either stability or delayed
progression of visual loss [2]. When medical and
laser therapies fail to control IOP, glaucoma
filtration surgery (GFS) is usually necessary. GFS
techniques lower the IOP by establishing an
surgical outflow channel through which the
aqueous humor drains continuously from the
anterior chamber to the sub-Tenon and
subconjunctival space [3].
Nevertheless, the long-term success of GFS is
often compromised by the relentless
wound-healing process ultimately blocking the
surgically created outflow pathway at the
conjunctival and episcleral plane. Diverse
molecular and cellular processes such as
collagen deposition, angiogenesis, and the
activation and proliferation of fibroblasts are
implicated in the healing process which
eventually obstructs aqueous outflow [4]. As a
result, glaucoma surgery often fails to
adequately control IOP and the patient’s visual
decline continues [5, 6]. The success of GFS has
improved considerably following the
intraoperative and postoperative application of
antimetabolites such as 5-fluorouracil and
mitomycin C. However, it should be
emphasized that the mechanism by which
these molecules prevent healing is nonspecific
and can lead to excessive collateral tissue
damage. Excessive prevention of wound
healing observed in antimetabolite-augmented
GFS is associated with complications such as
postoperative hypotony, infections, corneal
toxicity, and a thin-walled avascular bleb,
which is prone to leakage [7–9]. Consequently,
approaches to modulate the wound-healing
response with medications that have an
improved safety profile are under investigation.
Angiogenesis is a key element of the
wound-healing process and is essential for the
ultimate formation of granulation tissue.
Vascular endothelial growth factor (VEGF) is a
potent inducer of angiogenesis known to
promote the migration of inflammatory cells
and fibroblasts as well as having a direct effect
upon the activity of fibroblasts [10]. On the
basis of this hypothesis, the adjunctive use of
VEGF inhibitors has been recently tried in GFS
[11–14]. It has been postulated that the use of
these selective wound modulators may enhance
surgical efficacy and, at the same time, offer a
more favorable safety profile.
As a result of their mechanism of action,
anti-vascular endothelial growth factor
(anti-VEGF) molecules have been investigated
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and found to be clinically useful in several
conditions in which angiogenesis plays an
important role, e.g., neovascular glaucoma
(NVG) [15–17]. Importantly, most NVG cases
are caused by ischemic diseases such as diabetic
retinopathy and central retinal vein occlusion
[15–17]. Ocular ischemia initiates the
development and gradual growth of subtle
new vessels over the trabecular meshwork that
subsequently forms a fibrovascular membrane.
The development of this membrane obstructs
the aqueous humor outflow and causes a
significant IOP elevation leading ultimately to
a refractory secondary glaucoma [15–17]. This is
characterized as a secondary angle closure
glaucoma since the contraction of the
fibrovascular membrane pulls the peripheral
iris into the anterior chamber angle [18].
Comprehensive retinal laser photocoagulation
is currently considered the gold standard in
eliminating ischemia and the subsequent
neovascularization. However, the laser not
only destroys the ischemic retinal tissue
responsible for the vasoproliferative stimulus
but also damages healthy cells that are not
involved in the pathologic process of hypoxia
[19]. Moreover, it takes a few weeks to obtain a
meaningful regression of neovascularization
and most patients need intensive IOP-lowering
therapy before the beneficial effect of laser
photocoagulation is established. A number of
recent studies [20–25] have investigated the role
of anti-VEGF molecules in the management of
NVG. This research explores whether these
agents can facilitate IOP control and the
preservation of the integrity of healthy retinal
cells. It should be emphasized, however, that
their precise role as adjuvant therapy in this
pathological process is still under investigation.
This review examines the current role of
anti-VEGF drugs as adjuvant therapy in NVG
and their utility in modulating the
postoperative wound-healing response in GFS.
We searched the databases of the Cochrane
Library, Pubmed, and Embase from the time of
their inception to April 2016. This article is
based on previously conducted studies, and
does not involve any new studies of human or
animal subjects performed by any of the
authors.
ANTI-VASCULAR ENDOTHELIAL
GROWTH FACTORS
VEGF is a homodimeric glycoprotein
characterized by an amino acid homology
shared with platelet-derived growth factor [26].
The VEGF family of molecules consists of
various ligands [VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and placental growth factor (PIGF)]
with VEGF-A being the dominant mediator of
pro-angiogenic signaling. VEGF-A exists in five
isoforms that differ in the average chain lengths
(121, 145, 165, 189, and 206 amino acids).
VEGF165 (45 kDa) is the predominant isoform
and the key agent in neovascularization [27].
The function of these molecules is primarily
mediated by binding and activating two
transmembrane tyrosine kinase receptors,
VEGFR-1 and VEGFR-2 [28, 29]. Additionally,
VEGF binds to isoform-specific VEGF receptors
(neuropilins) expressed in endothelial and
non-endothelial cells [30, 31]. Several
therapies have been developed with the aim of
inhibiting VEGF and optimizing the
management of several ocular pathologies.
These therapeutic applications include three
VEGF inhibitors: bevacizumab, ranibizumab,
and aflibercept (Fig. 1).
Bevacizumab (BVZ) (Avastin; Genetech,
South San Francisco, CA, USA) is a full-size
recombinant humanized IgG1 kappa
monoclonal antibody against all isoforms of
VEGF. This molecule has a total molecular mass
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of 149 kDa, is N-glycosylated in its Fc region
and requires mammalian cell lines CHO DP-12
for production [32]. Its function is mediated by
binding to both transmembrane tyrosine kinase
receptors VEGFR-1 and VEGFR-2,
downregulating the mitogenic, angiogenic,
and permeability-enhancing effects of VEGF
[33]. BVZ was approved by the US Food and
Drug Administration (FDA) in 2005 for the
treatment of colorectal and breast cancers, but
it is also used extensively off-label in several
ocular conditions [34].
Ranibizumab (RBZ) (Lucentis; Genetech,
South San Francisco, CA, USA) is an antibody
binding fragment (Fab) of a recombinant
humanized IgG1 kappa isotype murine
monoclonal antibody against all isoforms of
VEGF, thereby preventing binding of VEGF to
its receptors VEGFR-1 and VEGFR-2 [35]. RBZ
was developed by selection of a Fab genetically
engineered to obtain an increased binding
affinity and inhibition of VEGF [36, 37] that
differs from the corresponding part in BVZ by
six amino acids. RBZ has a total molecular mass
of 48 kDa, is not glycosylated, and can be easily
produced in Escherichia coli cells by
recombinant DNA technology [38]. Owing to
its simple structure and its higher affinity for
VEGF, RBZ requires lower molar amounts than
BVZ to neutralize an equal amount of VEGF
[39, 40]. It was approved by the FDA in 2006
and is indicated in adults for the treatment of
choroidal neovascularization due to age-related
macular degeneration (AMD), the treatment of
visual impairment due to diabetic macular
edema (DME), macular edema secondary to
retinal vein occlusion, and for the treatment
of visual impairment due to choroidal
neovascularization secondary to pathologic
myopia.
Aflibercept (AFB) (Eylea; Regeneron
Pharmaceuticals, Tarrytown, NY, USA) is a
glycosylated recombinant fusion protein with
a total molar mass of 115 kDa. AFB is composed
of the combination of a fusion of the second Ig
domain of human VEGFR-1 and the third Ig
binding domain of human VEGFR-2 with the
constant fragment crystallizable portion of the
human IgG1 [41]. Produced from hamster ovary
cells, AFB binds to all isoforms of VEGF-A with a
higher affinity than BVZ and RBZ, also binding
to VEGF-B and PIGF. It forms stable, inert,
Fig. 1 Anti-vascular endothelial growth factor drugs for ocular diseases
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homogeneous complexes with VEGF that do
not induce platelet aggregation or tissue
deposits in the systemic circulation [42],
unlike what has been hypothesized for
heterogeneous multimeric immune complexes
formed by BVZ and VEGF [43]. AFB was
approved by the FDA for the treatment of
choroidal neovascularization due to AMD,
DME, and diabetic retinopathy in patients
with DME (in 2011, 2014, and 2015,
respectively). European Commission regulators
subsequently approved AFB in 2015 for the
treatment of visual impairment due to macular
edema secondary to central or branch retinal
vein occlusion.
ANTI-VEGF DRUGS IN GLAUCOMA
MANAGEMENT
Neovascular Glaucoma
As stated above, NVG is a potentially
devastating form of secondary angle-closure
glaucoma. As a result of either delayed
diagnosis or insufficient management, the
prognosis is often poor and can result in visual
loss and uncontrollable pain. Clinical
conditions associated with ischemia such as
proliferative diabetic retinopathy, ischemic
central retinal vein occlusion, and ocular
ischemic syndrome are the most common
entities associated with the development of
NVG [44], although in some cases NVG is
related to inflammation without clear-cut
evidence of ischemia [45]. The pathogenesis of
NVG involves the promotion of
neovascularization in the anterior chamber
angle and specifically the iris.
Neovascularization is mediated by
pro-angiogenic factors produced in the retina
as a result of ischemia; these factors eventually
diffuse into the anterior chamber. As a result, a
fibrovascular membrane forms in the iris, the
anterior chamber angle, or both. The
subsequent contraction of the membrane pulls
peripheral iris into the angle leading to the
development of secondary angle-closure
glaucoma [18]. At this point IOP reaches high
levels and it is difficult to control it with
conventional antiglaucoma therapies [17].
The successful management of NVG requires
adequate control of IOP as well as a targeted
therapy directed at the ischemic condition
causing the neovascularization. Panretinal
photocoagulation (PRP) is still the gold
standard therapy for those cases in whom
NVG arises from an ischemic retina [19]. PRP
destroys the ischemic tissue responsible for the
vasoproliferative stimulus, reducing the global
oxygen demand of the retina as well as
eliminating the synthesis of vasoproliferative
factors. However, PRP cannot selectively target
pathological tissues and damages healthy
tissues that are not involved in the process of
hypoxia-induced neovascularization [19]. For
that reason, although VEGF levels decrease
and neovascularization generally regresses after
PRP [46], this treatment causes permanent
visual field damage [19]. In addition, the
regression of neovascularization after PRP is
not immediate and patients usually need close
monitoring and combined local and systemic
therapy to control elevated IOP for several
weeks. Furthermore, this therapeutic approach
is limited to eyes with clear media. In contrast,
the presence of media opacities (e.g., corneal
edema or lens opacities) significantly limits or
completely eliminates this therapeutic
approach. Therefore, there is a need to develop
specific targeted therapies that will reduce
angiogenetic factors and subsequent
neovascularization while at the same time
preserving healthy retinal cells. Early evidence
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shows that anti-VEGF molecules are promising
in that respect [20–25].
Key Role of VEGF in Neovascular Glaucoma
As stated before VEGF is involved in the
physiological stimulation of angiogenesis, the
process that restores oxygen supply to tissues
when blood flow is inadequate [47]. In addition,
this factor plays an important role in blood
vessel formation when the pre-existing ones are
blocked, for instance during embryonic
development [48, 49] or following injury [50].
VEGF behaves as an endothelial cell mitogen
[26, 51], a chemotactic agent for
bone-marrow-derived endothelial cell
precursors [52], an inducer of vascular
permeability [53, 54], and a survival factor for
endothelial cells through inhibition of
apoptosis [55]. On the other hand, VEGF
overexpression leads to the formation of
pathologic blood vessels. Recent studies have
demonstrated the significant association
between increased VEGF levels in the eye and
pathological conditions in which
neovascularization or inflammation are
involved, such as proliferative diabetic
retinopathy [56], NVG [57], uveitis [58], or
age-related macular degeneration [15].
Anti-VEGF Therapy in Neovascular Glaucoma
In the setting of NVG, a number of studies have
investigated the use of anti-VEGF antibodies,
such as BVZ, RBZ, and AFB by topical,
intracameral, or intravitreal administration
(Table 1). In a pilot study published by
Waisbourd et al. [59] the efficacy of topically
applied BVZ for the treatment of NVG was
evaluated. Eight patients were treated with
topical BVZ (25 mg/mL) four times daily for
2 weeks. The authors observed a mean IOP
reduction of 6.1 mmHg and noted that three
patients had clinical regression of iris
neovascularization [59]. The intracameral
administration of BVZ reduced the number of
patients requiring surgical treatment of NVG,
whereas some other patients became candidates
for filtration surgery [60]. In a separate study, a
decreased leakage from new iris vessels was
observed 1 day after an intracameral injection
of BVZ [61].
In a 12-month prospective clinical series
published by Lu¨ke et al. [62], 10 cases with
NVG received intraocular injections of RBV
(0.5 mg/0.05 mL). According to the authors,
RBV appeared to be beneficial owing to its
anti-angiogenic properties and its ability to
prevent or halt anterior chamber angle
occlusion [62]. In the same context, Grover
et al. [63] reported a considerable reduction in
aqueous humor VEGF concentrations following
an intracameral injection of BVZ. Furthermore,
in a randomized trial of 26 patients treated with
intravitreal BVZ, a significant IOP reduction was
noted as well as a significant regression of
neovascularization compared to sham
injections [64]. However, the use of
Table 1 Summary of studies employing anti-VEGF drugs in glaucoma ﬁltration surgery and neovascular glaucoma
Route of administration Glaucoma ﬁltration surgery Neovascular glaucoma
Topical [80, 83, 101, 105] [59]
Subconjunctival [77–80, 82–86, 88] –
Intracameral [77] [59–61, 63]
Intravitreal [78, 79, 87, 90] [25, 59, 62, 64–66]
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intravitreal BVZ in a later study did not
significantly reduce the frequency of hyphema
and fibrin formation in the anterior chamber
1 day after surgery and a single injection of the
anti-VEGF was insufficient to completely
eliminate iris neovascularization [65].
Similarly, in a retrospective review recurrent
anterior segment neovascularization was seen
after a single intravitreal injection of BVZ [66].
It is worth noting that these authors reported
that trabeculectomy provided a protective effect
against the recurrence of anterior segment
neovascularization [66].
In a more recent study, four patients with
newly diagnosed stage 1 or 2 NVG received an
intravitreal injection of AFB (2 mg) at the time
of diagnosis and then additional injections at
4 weeks, 8 weeks, and at 8-week intervals for
52 weeks [25]. Results showed that iris and
angle neovascularization regressed and IOP
was either stable or significantly reduced in all
patients at the end of the study [25].
Wound Modulation in Glaucoma
Filtration Surgery
The wound-healing process consists of four
continuous, overlapping, and well-orchestrated
phases: hemostasis, inflammation,
proliferation, and tissue remodeling. During
the healing process, several events take place
in a synchronized manner: (a) rapid hemostasis,
(b) inflammation, (c) mesenchymal cell
differentiation, proliferation, and migration to
the wound site, (d) controlled angiogenesis,
(e) regrowth of epithelial tissue over the wound
surface, and (f) synthesis, cross-linking, and
alignment of collagen to provide strength to
the healing tissue [67]. Contrary to many other
surgical procedures, the success of GFS relies on
inhibition of the wound-healing process.
Aggressive healing at the conjunctival and
episcleral plane are the major causes of
surgical failure, eventually leading to
suboptimal or poor IOP control. Collagen
accumulation, angiogenesis, and the activation
and proliferation of fibroblasts in these areas
block the surgically created fistula and prevent
controlled aqueous outflow [4].
Bleb vascularity is a central parameter
associated with the success of GFS. The
formation of an avascular filtering bleb in
the postoperative period is generally
associated with a favorable outcome, whereas
increased vascularity of the filtering bleb is
usually seen as a predictor of failure [68].
Accordingly, it has been established that the
prognosis of GFS could be significantly
improved by decreasing the vascularity of a
filtering bleb by inhibiting angiogenesis [11].
It is well documented that the concomitant
use of antimetabolites such as 5-fluorouracil
(5-FU) and mitomycin C (MMC) has improved
the success of GFS. However, the use of these
molecules has also been associated with an
increased complication rate in the
postoperative period as a result of their
nonspecific mechanism of action [7–9]. By
inducing excessive cell death, antimetabolites
can cause extensive ocular tissue alterations
that cause postoperative hypotony, corneal
toxicity, and a thin-walled avascular bleb
susceptible to leakage and postoperative
infections. Consequently, alternative safer
forms of wound-healing modulation with
more specific agents are under investigation.
Since VEGF plays a key role in both
physiological and pathological angiogenesis,
the use of VEGF inhibitors as selective wound
modulators with a more favorable safety
profile has been intensively studied over the
past few years.
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Role of VEGF in Wound Modulation
VEGF is produced by different cell types
including endothelial cells [69], macrophages
[70], fibroblasts [71], platelets [72], neutrophils
[73], and smooth muscle cells [74]. All cell types
participate in the wound-healing process so
VEGF stimulates multiple components of the
wound-healing cascade, such as angiogenesis,
epithelization, and collagen deposition [75].
Among the five existing isoforms of VEGF, the
predominant VEGF165 together with VEGF121
are related to blood vessel growth, while
VEGF189 is associated with fibrosis [11].
Interestingly, some authors have reported a
significant correlation between the outcome of
glaucoma surgery and VEGF levels in aqueous
humor and Tenon’s tissue. Specifically, VEGF
levels have been reported to be higher in
glaucoma patients who experienced failed GFS
in comparison to patients without glaucoma or
patients with successful GFS [76]. Moreover, the
ultimate success of the operation and the 1-year
level of IOP in patients with primary open-angle
glaucoma have been associated with the
aqueous humor and Tenon’s tissue levels of
VEGF [76], indicating the potential utility of
anti-VEGF therapy in promoting the success of
GFS.
Anti-VEGF Therapy in GFS
A number of studies have investigated the
topical, intracameral, subconjunctival, and
intravitreal administration of anti-VEGF
antibodies such as BVZ and RBZ in the context
of GFS (Tables 1, 2). In an experimental model
of GFS in rabbits, the bleb area could be
increased if BVZ was applied into the anterior
chamber (5 mg) and the subconjunctival space
(2.5 mg) during trabeculectomy. However, the
authors did not detect significant differences in
the IOP of these animals between treated and
control eyes 29 days after surgery [77]. Similar
results were obtained in a study in which
subconjunctival injection of 1.25 mg BVZ,
5-FU, or balanced salt solution (BSS; control)
was performed in rabbits (n = 42) that
underwent trabeculectomy [78]. These authors
did report longer bleb survival in the BVZ group
in comparison to the 5-FU and control groups,
but the mean IOP across all groups was similar
[78]. In a different study, subconjunctival
injections of BVZ (1.25 mg) generated bigger
and higher blebs and lower mean IOP in a rabbit
model of filtration surgery, in comparison with
intravitreal injections of BVZ, 5-FU, or BSS [79].
The use of anti-VEGF therapy for preventing
bleb failure in patients undergoing single-site
phacotrabeculectomy for primary open-angle
glaucoma or chronic angle-closure glaucoma
has been studied in a randomized controlled
clinical trial [80]. In this pilot study, 38 patients
were divided into three groups treated with
conventional MMC application (0.03%),
subconjunctival BVZ (1.25 mg/0.05 mL), or
soaked sponges of BVZ (1.25 mg/mL). In both
BVZ groups, bleb vascularity increased
progressively over the 6-month follow-up. The
authors concluded that in their small sample of
patients, subconjunctival injections of BVZ (but
not soaked sponges of BVZ) were equally
effective in reducing IOP in comparison to
MMC. The authors suggested that larger
clinical trials with a similar study design are
needed to corroborate these findings [81]. Tai
Table 2 Summary of studies included in the review on the
intraoperative and postoperative application of anti-VEGF
drugs in glaucoma ﬁltration surgery, by intracameral (IC),
subconjunctival (SC), intravitreal (IV) administration, or
applied via soaked sponges (SS)
Intraoperative [77] (IC, SC), [79] (SC, IV), [80] (SC,
SS), [83] (SC), [84] (SC)
Postoperative [78] (SC), [82] (SC), [85] (SC), [86]
(SC), [87] (IV), [88] (SC)
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et al. reported a 6-month comparative results
for patients with failed trabeculectomy and
ExPRESS shunts treated with needling with
BVZ and MMC versus needling with MMC
alone. All patients received a subconjunctival
injection of MMC (0.04 mg) at the beginning of
the procedure. Then, they were randomized to
receive either subconjunctival BVZ (1 mg) or
BSS (control group) after the bleb needling. The
difference in success rates between the groups
was not statistically significant, despite the fact
that the BVZ plus MMC group had blebs with
less pronounced vascularity and greater extent
[82].
A recent study by Pro et al. analyzed the
efficacy and safety of intraoperative adjunctive
RBZ versus MMC in primary glaucoma
trabeculectomy surgery [83]. This prospective,
open-label randomized pilot study included 24
patients who received a subconjunctival
injection of RBZ (0.5 mg) or an MMC (0.4 mg/
mL) soaked pledget inserted in the sub-Tenon
space for 1.5 min during surgery, prior to
creating the scleral flap. Reduction in IOP was
only statistically significant in the MMC group.
At 6 months, the RBZ group had more diffuse
and less vascular blebs than the group with
MMC alone. The authors reported that
although large-scale studies are needed to
recommend RBZ over MMC as the only
surgical adjunctive, it is possible that the
duration of action of a one-time
subconjunctival injection was too short to
influence long-term episcleral and
subconjunctival wound healing.
Nilforushan et al. [84] compared the
outcome of trabeculectomy with
subconjunctival BVZ or MMC in a prospective,
randomized, comparative study performed in
34 patients with uncontrolled glaucoma. An
IOP reduction of 34% and 56% was reported at
6 months in the BVZ and MMC groups,
respectively. These authors observed that the
MMC group displayed significantly better IOP
control whereas the BVZ group required more
antiglaucoma medications for IOP control. In
the study reported by Grewal et al. [85], 12
patients underwent trabeculectomy with
subconjunctival BVZ (1.25 mg), and the mean
IOP decreased from 24.4 mmHg to 11.6 mmHg
(52%), with no medications at 6 months after
surgery. Their results included one case of
choroidal detachment. Akkan and Cilsim [86]
reported the effectiveness of trabeculectomy
with subconjunctival BVZ or MMC. These
authors observed a significant reduction of IOP
in both cases. There was a decrease in IOP of
41% after 1 year in the BVZ group and 46% in
the MMC group. However the MMC group
showed more effective control of IOP at levels
below 12 mmHg and a higher number of
patients required antiglaucoma medications in
the BVZ group.
Recently, Kahook [87] investigated the
outcomes of trabeculectomy using
intraoperative intravitreal RBZ with topical
MMC versus topical MMC alone. Both groups
exhibited similar IOP control, but patients
treated with combined intravitreal RBZ and
topical MMC had more diffuse blebs with
reduced vascularity. Some authors have
compared the outcome of bleb revision with
needling using BVZ versus MMC as an adjuvant
[82, 88]. Both modalities were effective when
employed concomitantly with needling,
offering approximately 30% reduction
compared to baseline IOP with the MMC
exerting a longer-term effect consistent with
the fact that it exerts a more permanent and
irreversible cellular effect compared to BVZ.
MMC inhibits conjunctival and scleral
fibroblast proliferation at the surgical site but
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may also cause a certain degree of ciliary body
toxicity, thus decreasing aqueous humor
production [89].
The route of administration may become an
important consideration in the use of
anti-VEGF agents. Intravitreal administration
was demonstrated to be the most effective in
rabbits [90]. However, subconjunctival
administrations result in a longer half-life in
both the iris/ciliary body and the
retina/choroid, in comparison with intravitreal
application. This effect can be explained by the
storage effect afforded by the scleral tissue
matrix. On the other hand, subconjunctival
administrations offer direct modulation of the
conjunctival wound-healing process. Although
more research is needed to determine the
optimal dose of BVZ in these settings,
subconjunctival injections containing 1.25 or
2.5 mg of drug were most commonly employed
[84, 86].
SAFETY AND TOLERABILITY
As mentioned previously, in order to delay the
wound-healing process, antimetabolites such as
MMC and 5-FU have been used in
trabeculectomy because of their inhibition of
fibroblast migration and proliferation that
would otherwise lead to scarring over the
filtration site [91]. MMC is used
intraoperatively more than twice as often as
5-FU [92] and has been shown to significantly
reduce IOP and the risk of surgical failure in
eyes that have undergone no previous surgery
and in eyes at high risk of failure [93]. On the
other hand, antimetabolites are associated with
complications such as hypotony, cystic
avascular bleb, bleb leak, bleb infection, and
endophthalmitis [7–9]. Because of these, there is
a need for more targeted and effective
anti-scarring interventions. It has been proven
that at the filtration site, VEGF could modify
fibroblast activity and stimulate collagen
cross-linking and contraction, resulting in scar
formation [77]. Moreover, higher VEGF levels in
Tenon’s tissue preoperatively are associated
with a worse outcome following
trabeculectomy surgery [9].
When using BVZ in filtration surgery, one
should consider that in several of these studies
bleb encapsulation is more frequent with BVZ
compared to MMC. In addition, it has been
suggested that MMC and 5-FU are more
effective than BVZ at reducing IOP and
achieving a diffuse filtering bleb in primary
trabeculectomy [78, 84, 86, 94]. An explanation
for this phenomenon involves the direct
toxicity that MMC or 5-FU produces over the
ciliary epithelium, which might decrease
aqueous humor secretion and, subsequently,
IOP.
Vandewalle et al. reported the interesting
observation that bleb vascularity begins to
increase 3 months after the administration of
BVZ [95]. While this effect may decrease the
incidence of cystic avascular blebs often
developed following MMC-augmented surgery,
it also raises concerns about possible bleb failure
in the future. Similar observations were made by
Sengupta et al. [80] after subconjunctival
administration of BVZ: higher and more
avascular blebs were present 1 month after
treatment but the effect did not persist over a
6-month period. BVZ may have a limited
activity to different subtypes of fibroblasts in
encapsulating tissue or might not have a long
enough duration of effect on inflammatory
mediators.
A toxic effect of 5-FU and MMC on corneal
endothelial cells has been described when these
agents are administered as subconjunctival
injections following filtration procedures.
Consequently, the use of an anti-VEGF drug
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and specifically BVZ may be a safer option with
regard to corneal toxicity [96–98]. Additionally,
subconjunctival injections of MMC may cause
limbal stem cell deficiency [99]. In the study
carried out by Sengupta et al. [80], no toxic
effects of 1.25 mg of BVZ were seen in the
corneal epithelium or endothelium. Moreover,
after 6 months of follow-up, subconjunctival
injections of BVZ had a slightly better safety
profile compared to the application of sponges
soaked with MMC or BVZ. In vitro studies have
concluded that BVZ is not toxic to human
corneal cells, including corneal endothelial
cells, at doses often used for the treatment of
corneal neovascularization [100]. A pilot study
showed that BVZ eyedrops can sufficiently
penetrate the corneal stroma and reach the
anterior chamber when administered soon after
alkali burns. The same study showed that BVZ
eyedrops can significantly reduce corneal
damage caused by alkalis [101].
In conclusion, several comparison studies
have shown that the safety and efficacy of
anti-VEGF therapy are not significantly
different from those of current anti-scarring
medications. Considering BVZ, it is an effective
and safe agent commonly used in patients with
retinal diseases and neovascularization of the
anterior segment [102–104]. However, as an
adjuvant for trabeculectomy, one should also
consider the contraindications for its use,
including pregnancy, breast feeding,
uncontrolled systemic hypertension, and
cerebrovascular accidents or transient ischemic
attacks 1 month prior to injection. Moreover,
complications such as conjunctival necrosis
have been reported following subconjunctival
BVZ [80] and intravitreal RBZ [105] injection.
More specific anti-VEGF agents, possibly
targeting VEGF189, could prove more potent
and safer. In addition, agents with longer
duration of effect would be necessary for the
long-term success of GFS.
A clinical study with a larger cohort and
longer follow-up, such as the one described by
Bochmann et al. [106], would confirm and more
accurately highlight the role of anti-VEGF
agents in glaucoma surgery. Moreover,
targeting the wound-healing process with
combination therapy using both
anti-angiogenic and anti-fibrotic agents should
be further investigated, as the processes of vessel
formation and fibrosis occur at different times
in the wound-healing cascade.
ADVANTAGES AND POTENTIAL
DRAWBACKS
A number of studies investigating the use of
anti-VEGF agents or antimetabolites in GFS or
the management of NVG have demonstrated
that these medications can improve surgical
outcomes. However, anti-VEGF agents have yet
to demonstrate advantages over the more
established anti-scarring agents commonly used.
On the other hand, the short-acting effect of
anti-VEGF agents is an important
inconvenience to consider. Histological studies
have shown that maximum proliferation of
subconjunctival fibroblasts, an important
factor in bleb failure, occurs on the third to
fifth postoperative day [107, 108]. Since it is
known that the half-life of BVZ is 3–4 days,
multiple injections of anti-angiogenic agents
are needed to overcome this limitation. At the
same time, the pharmacokinetics of BVZ after
subconjunctival injections requires further
study. The use of BVZ in glaucoma is currently
off-label, and several issues need to be addressed
in this regard, such as the duration of action
and the profile of toxicity to the corneal
endothelium, lens, and trabecular meshwork.
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Liu and coworkers recently published a
systematic review and meta-analysis of
randomized controlled trials to compare the
efficacy and safety of BVZ with MMC employed
at different levels [109]. Results showed that
while BVZ seemed to be an effective agent with
regard to complete success rate, IOP, and
antiglaucoma medication reduction when
compared with placebo, it significantly
increased the risk of bleb leakage and the rate
of encysted blebs in the studies analyzed, in
comparison with MMC as well. However, the
authors recognized limitations in this study
which have to be pointed out, such as the small
sample size of the studies analyzed, the varying
definitions of surgical success, the absence of
patient stratification into different types of
glaucoma or the risk of surgical failure, among
others.
As mentioned above, the conventional
treatment for NVG is PRP. However, a poor
view of the retina may prevent adequate PRP. In
these cases, intravitreal administration of
anti-VEGF medications may prevent the
growth of abnormal blood vessels. However,
the possibility of adverse events related to the
intravitreal route of administration has to be
taken into account: conjunctival hemorrhage,
eye pain, vitreous floaters, increased intraocular
pressure, and intraocular inflammation [110].
Other less frequent but sight-threatening
adverse events that may occur as a result of
the intravitreal injection route include
endophthalmitis and retinal detachment.
In summary, GFS augmented with
antimetabolites may provide lower IOP but is
more likely to cause hypotony or bleb-related
complications. Therefore, anti-VEGF agents
may have a dual role as postoperative
wound-healing modulators as well as
‘‘antimetabolite-sparing’’ medications that may
ensure smaller, and thus safer, doses of MMC or
5-FU can be used effectively. Further research
on the surgical treatment of glaucoma with
adjunctive use of anti-VEGF is needed.
Additionally, side effects of repetitive
anti-VEGF injections, including trabecular
meshwork toxicity, should be investigated.
Prospective randomized multicenter clinical
trials are still lacking, and there is clearly a
need for studies that will refine treatment
protocols by examining safety and efficacy of
different dosages, routes of delivery, or
frequency of administration.
Considering NVG, unfortunately the
existing literature showing excellent response
to intravitreal anti-VEGF agents consists of
retrospective studies or case series [57].
Well-designed, controlled, prospective studies
are needed to confirm these results. Until
evidence from high-quality studies becomes
available, decisions in clinical practice will
need to be based on the existing evidence, the
physician’s experience, and the patient’s
preferences.
CURRENT AND FUTURE
DEVELOPMENTS
The use of anti-VEGF agents in glaucoma
filtration surgery and neovascular glaucoma
needs to be supported by more evidence.
Several issues have to be addressed such as the
duration of action and the toxicity profile on
corneal endothelium, lens, and trabecular
meshwork. It is also important to precisely
characterize the pharmacokinetics of the
different antibodies and determine whether
these molecules are capable of blocking all
VEGF isomorphs at once. Considering BVZ,
poor surgical results using a single dose may
justify future trials using multiple doses.
Notwithstanding cost, additional injections of
BVZ in the postoperative period may improve
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the survival of trabeculectomy to a degree
comparable to that observed with MMC. In
order to improve the efficacy of BVZ in this
context, parameters such as dose, route of
administration, and type of formulations will
need to be considered in future studies.
The effects of anti-VEGF agents for treating
NVG are temporary, generally lasting 4–6 weeks
[111]. It is also known that anti-VEGF agents
alone may not be sufficient to treat NVG caused
by conditions with a prolonged natural history.
Nonetheless, the combination of anti-VEGF and
conventional treatments has the potential to be
more effective than conventional treatments
alone by virtue of a dual mechanism of action.
A further advantage might also be that
combined treatments with anti-VEGF and
conventional treatments may offer a longer
duration of action, allowing a longer interval
between injections.
There is an increasingly apparent need for
the development of novel systems that allow
the delivery of anti-VEGF agents alone or in
combination with conventional therapies. In
this context, it is crucial that these therapeutic
tools provide new alternatives with enhanced
therapeutic effects and longer dosing intervals,
thus allowing the attainment of therapeutic
concentrations over an extended period of time.
On the positive side, a wide range of
formulations, biodegradable materials, and
pharmaceutical technologies have currently
reached different stages of development. It is
only a matter of time before a viable alternative
becomes clinically available.
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